AWHLOTCIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Aspira Women's Health Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.22−0.01 (-2.61%)
Close on Oct 19, 2026
- Market cap
- $9.91M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
1724.5%+1697.9 pts over 5 years
Operating margin
-2307.0%−1920.4 pts over 5 years
Net margin
-3725.9%−3341.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +8475.0% | -65.3% | -40.6% | -16.9% | |
| Gross profit | +8.0% | +11.0% | +36.8% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -140.5% | -194.0% | 269.2% | |
| Return on assets | -103.3% | -107.1% | -233.5% | |
| Current ratio | 2.39 | 3.10 | 1.17 | |
| Debt to equity | 0.49 | 0.49 | -0.26 | |
| Net debt to EBITDA | 0.24× | 0.67× | -0.00× | |
| Inventory turnover | 30.0× | 124.2× | -19.1× | |
| Capex to revenue | 47.7% | 10.5% | 4.7% | |
| Diluted shares | 3M | 7M | 34M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Aspira Women's Health generated $93.50M from operations and spent $493.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$93.50M
Used
$493.00K
Capital expenditure$493.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-3725.9%
×Asset turnover0.06×
×Equity multiplier-1.15×
=Return on equity, FY2025269.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -3725.9% | 0.06× | -1.15× | 269.2% |
| FY2024 | -327350.0% | 0.00× | -2.38× | 531.4% |
| FY2023 | -19.2% | 7.36× | 5.12× | -723.5% |
| FY2022 | -365.2% | 0.28× | 1.57× | -160.9% |
| FY2021 | -464.8% | 0.22× | 1.52× | -158.7% |
| FY2020 | -385.0% | 0.28× | 1.81× | -194.0% |
| FY2019 | -335.8% | 0.36× | 1.59× | -191.8% |
| FY2018 | -372.5% | 0.32× | 1.79× | -215.4% |
| FY2017 | -336.3% | 0.40× | 2.16× | -292.8% |
| FY2016 | -566.5% | 0.18× | 1.36× | -140.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$12.78M
- Cash generatingOperating cash flow above zero-$7.03M
- Return on assets improvedROA up on the prior year-209.1% → -232.7%
- Earnings backed by cashOperating cash flow above net income-$7.03M vs -$12.78M
- Less leverageLong-term debt to assets fell23.3% → 19.1%
- Better liquidityCurrent ratio rose0.76 → 1.17
- No dilutionShare count did not rise14M → 34M
- Gross margin improvedGross margin up on the prior year136975.00% → 1724.49%
- More efficientAsset turnover rose0.00 → 0.06